hello and welcome to our look ahead to what the the papers will be bringing us tomorrow. with me are arejessica elgot, deputy political editor of the guardian and katy balls, deputy political editor of the spectator. welcome back. let s look at what is in. the metro, which headlines prince philip leaving hospital after 28 days to be reunited with the queen at windsor. an exclusive in the huffington post which says the foreign secretary told officials that britain would seek trade deals with countries that have breached international human rights standards. the financial times follows up on that story which it says have led to accusations from some tory mps that borisjohnson is going soft on china. the vaccine chaos in europe is the top story in the telegraph with brussels blaming eu governments of stockpiling jabs. the guardian headlines the growing pressure on borisjohnson to launch a public inquiry into britain s handling of covid 19. and the mail leads with the con
of biblical texts dating almost from the time of christ. hello and welcome if you re watching in the uk or around the world stay with us for the latest news and analysis from here and across the globe. sweden and latvia are the latest eu member states to suspend use of the oxford astrazeneca vaccine following concerns about possible side effects. france, germany, spain and italy have all said they re awaiting the conclusions of an investigation by the european medicines agency which are due on thursday. but the agency has already said today there s no indication that the astrazeneca vaccine causes side effects such as blood clots. our medical editor fergus walsh has more details. this vaccine saves lives, of that there is no doubt. and yet in the middle of a pandemic, with thousands dying every day in europe from covid. germany, france, italy, more than a dozen eu countries have temporarily suspended using the astrazeneca jab. why? the concern is blood clots. astrazeneca
Amid concerns regarding potential side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant on Tuesday reiterated its commitment to patient safety.
1. Market Overview:The global cough syrup market was valued at $5,232.73 million in 2019, and is projected to reach $6,108.25 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.CAGR: 2.8%Current Market Size: USD 5.2 BillionFastest Growing Region: APACLargest Market: North AmericaProjection Time: 2019-2027.